Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

In my opinion, thanks in part to Blincyto, Enbrel, Imdelltra, Tezspire, and Amjevita/Amgevita, Amgen is getting closer to the leaders in these markets, namely AstraZeneca (AZN) and Johnson ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the US in January.

Two adalimumab biosimilars (Amjevita and Imraldi ... Co-authors reported relationships with AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Meyers ...